Core Insights - Amarin Corporation has reported financial results for Q4 and full year 2025, highlighting the impact of strategic initiatives and a refined business model on operational efficiencies and market positioning [1][2]. Financial Performance - Total net revenue for Q4 2025 was $49.2 million, a decrease of 21% from $62.3 million in Q4 2024 [3][5]. - Operating expenses decreased by 31% to $29.5 million in Q4 2025 from $43.0 million in Q4 2024, primarily due to cost-saving measures [3][6]. - The operating loss narrowed significantly to $6.3 million in Q4 2025, an improvement of 88% compared to a loss of $52.5 million in Q4 2024 [3][10]. - Net loss improved to $(1.2) million in Q4 2025 from $(48.6) million in Q4 2024, reflecting a 97% reduction [3][11]. Revenue Breakdown - U.S. product revenue for Q4 2025 was $41.1 million, down 7% from $44.2 million in Q4 2024 [4]. - European product revenue decreased by 42% to $2.3 million, while Rest-of-World (ROW) revenue fell by 74% to $3.1 million [5]. - Licensing and royalties revenue increased by 20% to $2.7 million in Q4 2025 compared to $2.2 million in Q4 2024 [5]. Cost Management - Cost of goods sold (COGS) decreased by 64% to $26.1 million in Q4 2025, influenced by a one-time inventory restructuring charge in the previous year [6][7]. - Selling, general, and administrative (SG&A) expenses dropped by 46% to $20.1 million, attributed to the Global Restructuring Plan [6][8]. - Research and development (R&D) expenses remained consistent with the prior year at $5.4 million [8]. Cash Position - The company reported total cash and investments of $302.6 million as of December 31, 2025, an increase from $294.2 million in the previous year [11]. - Amarin remains debt-free, positioning itself for future growth and operational priorities in 2026 [11]. Strategic Initiatives - Amarin has entered a long-term partnership with Recordati S.p.A. to expand the commercialization of VAZKEPA in Europe, enhancing its international commercial strategy [2][1]. - The company has published a total of 45 publications related to VASCEPA/VAZKEPA, furthering the scientific knowledge base supporting its cardiovascular products [1].

Financial Performance - Total revenue for Q1 2025 was $42.0 million[14, 21] - U S revenue was $35.7 million, a ~26% year-over-year reduction[21] - Europe revenue was $5.4 million, a ~284% year-over-year increase[14, 21] - Operating expenses for Q1 2025 were $41.9 million, an 8% reduction year-over-year[14, 19] - The company maintained a strong cash position with $281.8 million and no debt[14, 24] Business Updates - Achieved sequential growth in in-market demand across all European markets where VAZKEPA was launched, particularly in Spain, the UK, and CEE[13] - Secured pricing and reimbursement in Austria and continued progress in other EU markets[13] - CSL's efforts led to VAZKEPA's inclusion in the National Heart Foundation/Cardiac Society Acute Coronary Syndrome guidelines in Australia[13] - Edding continued CVRR launch in the private pay market in China, working towards National Reimbursement Drug List (NRDL) review for 2026[13] Strategic Priorities - Drive growth in access and revenue in Europe and Rest of World markets[30] - Drive efficient VASCEPA U S revenue generation[30] - Support research that reinforces VASCEPA science and therapeutic value[30] - Maintain fiscal and operational discipline while pursuing all avenues to maximize shareholder value[30]